The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis

Diabetes Research and Clinical Practice

Volumn 109, Issue 2, 2015, Pages 378-388

  Mishriky, Basem M ^a   Cummings, Doyle M ^a   Tanenberg, Robert J ^b  

^a EAST CAROLINA UNIVERSITY   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

Author keywords

DPP4 I; Meta analysis; Metformin; Sulfonylurea; Type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; METFORMIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ADD ON THERAPY; ADVERSE OUTCOME; ARTICLE; CLINICAL EFFECTIVENESS; COUGHING; DATA ANALYSIS; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HUMAN; HYPOGLYCEMIA; INCIDENCE; META ANALYSIS; MUSCULOSKELETAL DISEASE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RHINOPHARYNGITIS; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; WEIGHT GAIN; WEIGHT REDUCTION; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; SULFONYLUREA COMPOUNDS;

EID: 84937971687     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2015.05.025     Document Type: Article

References (45)

1. Standards of medical care in diabetes. Diabetes Care 2014;37 (Suppl 1):S14-80.
2. Global guideline for Type 2 diabetes. Diabetes Research and Clinical Practice 2014;(104):1-52.
3. Bailey T. Options for combination therapy in Type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm. Am J Med 2013, 126:S10-S20.
4. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycemia in Type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35:1364-1379.
5. Garber A.J., Abrahamson M.J., Barzilay J.I., Blonde L., Bloomgarden Z.T., Bush M.A., et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract: Off J Am Coll Endocrinol Am Assoc Clin Endocrinol 2013, 19:327-336.
6. Deacon C.F., Holst J.J. Dipeptidyl peptidase-4 inhibitors for the treatment of Type 2 diabetes: comparison, efficacy and safety. Expert Opin Pharmacother 2013, 14:2047-2058.
7. Monami M., Dicembrini I., Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis: NMCD 2014, 24:689-697.
8. Zhang Y., Hong J., Chi J., Gu W., Ning G., Wang W. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas-a meta-analysis from randomized clinical trials. Diabetes Metab Res Rev 2014, 30:241-256.
9. Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gotzsche P.C., Ioannidis J.P., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009, 6:e1000100.
10. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions, version 5.1.0 [update March 2011]. The Cochrane Collaboration, 2011. http://www.cochrane-handbook.org/.
11. Elia N., Tramer M.R. Ketamine and postoperative pain-a quantitative systematic review of randomised trials. Pain 2005, 113:61-70.
12. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary. Control Clin Trials 1996, 17:1-12.
13. Guedes E.P., Hohl A., de Melo T.G., Lauand F. Linagliptin: farmacology, efficacy and safety in Type 2 diabetes treatment. Diabetol Metab Syndr 2013, 5:25.
14. McAlister F.A. The number needed to treat turns 20-and continues to be used and misused. CMAJ: Can Med Assoc J J Assoc Med Can 2008, 179:549-553.
15. Stang A., Poole C., Bender R. Common problems related to the use of number needed to treat. J Clin Epidemiol 2010, 63:820-825.
16. Wen L., Badgett R., Cornell J. Number needed to treat: a descriptor for weighing therapeutic options. Am J Health-System Pharm: AJHP: Off J Am Soc Health-System Pharm 2005, 62:2031-2036.
17. Derosa G., Bonaventura A., Bianchi L., Romano D., Fogari E., D'Angelo A., et al. Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with Type 2 diabetes. Diabet Med: J Br Diabet Assoc 2014, 31:1515-1523.
18. Forst T., Dworak M., Berndt-Zipfel C., Loffler A., Klamp I., Mitry M., et al. Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the beta cell of patients with Type 2 diabetes mellitus. Diabetes Obes Metab 2013, 15:576-579.
19. Kim H.S., Shin J.A., Lee S.H., Kim E.S., Cho J.H., Son H.Y., et al. A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with Type 2 diabetes with inadequate glycemic control on metformin. Diabetes Technol Ther 2013, 15:810-816.
20. Arechavaleta R., Seck T., Chen Y., Krobot K.J., O'Neill E.A., Duran L., et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with Type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2011, 13:160-168.
21. Ferrannini E., Fonseca V., Zinman B., Matthews D., Ahren B., Byiers S., et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with Type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009, 11:157-166.
22. Filozof C., Gautier J.F. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med: J Br Diabet Assoc 2010, 27:318-326.
23. Forst T., Anastassiadis E., Diessel S., Loffler A., Pfutzner A. Effect of linagliptin compared to glimepiride on postprandial glucose metabolism, islet cell function, and vascular function parameters in patients with Type 2 diabetes mellitus on ongoing metformin treatment. Diabetes Metab Res Rev 2014, 30:582-589.
24. Forst T., Uhlig-Laske B., Ring A., Graefe-Mody U., Friedrich C., Herbach K., et al. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. Diabet Med: J Br Diabet Assoc 2010, 27:1409-1419.
25. Gallwitz B., Rosenstock J., Rauch T., Bhattacharya S., Patel S., von Eynatten M., et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with Type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 2012, 380:475-483.
26. Goke B., Gallwitz B., Eriksson J., Hellqvist A., Gause-Nilsson I. Saxagliptin is non-inferior to glipizide in patients with Type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract 2010, 64:1619-1631.
27. Goke B., Gallwitz B., Eriksson J.G., Hellqvist A., Gause-Nilsson I. Saxagliptin vs. glipizide as add-on therapy in patients with Type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial. Int J Clin Pract 2013, 67:307-316.
28. Matthews D.R., Dejager S., Ahren B., Fonseca V., Ferrannini E., Couturier A., et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 2010, 12:780-789.
29. Nauck M.A., Meininger G., Sheng D., Terranella L., Stein P.P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with Type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007, 9:194-205.
30. Seck T., Nauck M., Sheng D., Sunga S., Davies M.J., Stein P.P., et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with Type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010, 64:562-576.
31. Srivastava S., Saxena G.N., Keshwani P., Gupta R. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of Type 2 diabetes mellitus inadequately controlled with metformin alone. J Assoc Physicians India 2012, 60:27-30.
32. Ahren B., Johnson S.L., Stewart M., Cirkel D.T., Yang F., Perry C., et al. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with Type 2 diabetes taking metformin. Diabetes Care 2014, 37:2141-2148.
33. Del Prato S., Camisasca R., Wilson C., Fleck P. Durability of the efficacy and safety of alogliptin compared with glipizide in Type 2 diabetes mellitus: a two-year study. Diabetes Obes Metab 2014, 16:1239-1246.
34. Berndt-Zipfel C., Michelson G., Dworak M., Mitry M., Loffler A., Pfutzner A., et al. Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with Type 2 diabetes mellitus-results from an exploratory study. Cardiovasc Diabetol 2013, 12:59.
35. Derosa G., Bonaventura A., Bianchi L., Romano D., Fogari E., D'Angelo A., et al. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in Type 2 diabetic patients. Metab: Clin Exp 2014, 63:957-967.
36. Gerstein H.C., Miller M.E., Byington R.P., Goff D.C., Bigger J.T., Buse J.B., et al. Effects of intensive glucose lowering in Type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
37. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D., et al. Glucose control and vascular complications in veterans with Type 2 diabetes. N Engl J Med 2009, 360:129-139.
38. Turnbull F.M., Abraira C., Anderson R.J., Byington R.P., Chalmers J.P., Duckworth W.C., et al. Intensive glucose control and macrovascular outcomes in Type 2 diabetes. Diabetologia 2009, 52:2288-2298.
39. WHO. Comparative safety and efficacy of glibenclamide in the elderly. April 2013 ed.,http://www.who.int/selection_medicines/committees/expert/19/applications/glibenclamide/en/
40. Erhardt W., Bergenheim K., Duprat-Lomon I., McEwan P. Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of Type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis. Clin Drug Investig 2012, 32:189-202.
41. Granstrom O., Bergenheim K., McEwan P., Sennfalt K., Henriksson M. Cost-effectiveness of saxagliptin (Onglyza(R)) in Type 2 diabetes in Sweden. Prim Care Diabetes 2012, 6:127-136.
42. Schwarz B., Gouveia M., Chen J., Nocea G., Jameson K., Cook J., et al. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with Type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. Diabetes Obes Metab 2008, 10(Suppl 1):S43-S55.
43. Terrin N., Schmid C.H., Lau J. In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias. J Clin Epidemiol 2005, 58:894-901.
44. Terrin N., Schmid C.H., Lau J., Olkin I. Adjusting for publication bias in the presence of heterogeneity. Stat Med 2003, 22:2113-2126.
45. Thornton A., Lee P. Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol 2000, 53:207-216.